NCT05463679Phase 3Suspended

Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.

Study sponsor: Aytu BioPharma, Inc. · AYTU

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-06Estimated
Enrollment · participants260Estimated
Source updated2024-03-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.